Windtree Therapeutics (NASDAQ: WINT) is down some 50% yesterday and premarket today. We did - no, really we did - agree that coincidences happen and that the fine news about the European patent award was just one of those. That it happened right around the time there was that stock offer on the table. No, no, really, that's all it is.
Of course, the two pieces of information operate in different directions concerning that WINT stock price. The issue of new stock will, through dilution, reduce the value of all other pieces of Windtree stock. On the other hand, the announcement of a patent might be thought to increase the value of a pharma development company. Not much perhaps, as the patent is the easy part - getting the data to gain approval to sell is the difficult one. But, you know, we'd expect perhaps the one announcement to pull in one direction, the other in another.
Windtree Therapeutics stock price from NASDAQAs it turns out they do seem to have pulled in different directions. As we can see above the patent announcement tripled and more the WINT price - there were near $15 levels at some points intraday. As time went on perhaps more weight was put on the money raising issue. One problem was that none of us were certain what price that new stock would be issued at. We know this morning. “On April 12, 2023, the last reported sale price of our common stock on the Nasdaq Capital Market was $4.48 per share. We have assumed a public offering price of $4.48 per share of common stock together with a common warrant to purchase one share of common stock, which represents the last reported sale price of our common stock as reported on the Nasdaq Capital Market on April 12, 2023. The final public offering price will be determined through negotiation between us and the underwriters in the offering and may be at a discount to the current market price. Therefore, the recent market price used throughout this prospectus may not be indicative of the final public offering price.”
Well, OK, we still don't know, but we do see their starting point. The normal starting point for a new stock offer is at a decent discount to prevailing market price. Here they're assuming at earlier market price - that's also a substantial discount to the price at the time of announcement, boosted as it is by the patent announcement.
Or, to put this another way around, a new issue at $4.48 is substantially dilutive if the market price is up at $15, as it has been, or even $6.60 as it was yesterday. Therefore the fall to today's levels of course.
As we say, of course coincidences happen, that's what the word means



